These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Matsumoto S; Kimura S; Segawa H; Kuroda J; Yuasa T; Sato K; Nogawa M; Tanaka F; Maekawa T; Wada H Lung Cancer; 2005 Jan; 47(1):31-9. PubMed ID: 15603852 [TBL] [Abstract][Full Text] [Related]
44. The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives. Tonyali O; Arslan C; Altundag K Expert Opin Pharmacother; 2010 Nov; 11(16):2715-25. PubMed ID: 20977404 [TBL] [Abstract][Full Text] [Related]
45. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model. Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338 [TBL] [Abstract][Full Text] [Related]
46. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948 [TBL] [Abstract][Full Text] [Related]
47. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733 [TBL] [Abstract][Full Text] [Related]
48. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. Koizumi M; Nakaseko C; Ohwada C; Takeuchi M; Ozawa S; Shimizu N; Cho R; Nishimura M; Saito Y Eur J Haematol; 2007 Nov; 79(5):382-91. PubMed ID: 17903213 [TBL] [Abstract][Full Text] [Related]
49. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration. Rossini M; Adami S; Viapiana O; Ortolani R; Vella A; Fracassi E; Gatti D J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654 [TBL] [Abstract][Full Text] [Related]
50. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Ottewell PD; Brown HK; Jones M; Rogers TL; Cross SS; Brown NJ; Coleman RE; Holen I Breast Cancer Res Treat; 2012 Jun; 133(2):523-36. PubMed ID: 21956211 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice. Okada S; Kiyama T; Sato E; Tanaka Y; Oizumi T; Kuroishi T; Takahashi T; Sasaki K; Sugawara S; Endo Y Tohoku J Exp Med; 2013 Oct; 231(2):145-58. PubMed ID: 24140868 [TBL] [Abstract][Full Text] [Related]
52. The critical role of bisphosphonates to target bone cancer metastasis: an overview. Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856 [TBL] [Abstract][Full Text] [Related]
53. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043 [TBL] [Abstract][Full Text] [Related]
54. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. Mitrofan LM; Pelkonen J; Mönkkönen J Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819 [TBL] [Abstract][Full Text] [Related]
55. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Marra M; Santini D; Meo G; Vincenzi B; Zappavigna S; Baldi A; Rosolowski M; Tonini G; Loeffler M; Lupu R; Addeo SR; Abbruzzese A; Budillon A; Caraglia M Int J Cancer; 2009 Nov; 125(9):2004-13. PubMed ID: 19530242 [TBL] [Abstract][Full Text] [Related]
56. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798 [TBL] [Abstract][Full Text] [Related]
57. The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid. Romani AA; Desenzani S; Morganti MM; Baroni MC; Borghetti AF; Soliani P Cancer Chemother Pharmacol; 2011 Mar; 67(3):557-67. PubMed ID: 20473610 [TBL] [Abstract][Full Text] [Related]
58. In vitro and in vivo effects of photodynamic therapy on metastatic breast cancer cells pre-treated with zoledronic acid. Akens MK; Wise-Milestone L; Won E; Schwock J; Yee AJ; Wilson BC; Whyne CM Photodiagnosis Photodyn Ther; 2014 Sep; 11(3):426-33. PubMed ID: 25176573 [TBL] [Abstract][Full Text] [Related]
59. Therapeutic approach of primary bone tumours by bisphosphonates. Moriceau G; Ory B; Gobin B; Verrecchia F; Gouin F; Blanchard F; Redini F; Heymann D Curr Pharm Des; 2010; 16(27):2981-7. PubMed ID: 20722622 [TBL] [Abstract][Full Text] [Related]
60. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Vogt U; Bielawski KP; Bosse U; Schlotter CM Oncol Rep; 2004 Nov; 12(5):1109-14. PubMed ID: 15492801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]